<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03583996</url>
  </required_header>
  <id_info>
    <org_study_id>HQ-US-SHUNT-1801</org_study_id>
    <nct_id>NCT03583996</nct_id>
  </id_info>
  <brief_title>The SHUNT-V Study for Varices</brief_title>
  <official_title>The HepQuant SHUNT Liver Diagnostic Kit for Likelihood of Large Esophageal Varices: The SHUNT-V Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HepQuant, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HepQuant, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to validate the Disease Severity Index (DSI) from the HepQuant&#xD;
      SHUNT Liver Diagnostic Kit (Test) for likelihood of large esophageal varices.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to validate the Disease Severity Index (DSI) from the HepQuant&#xD;
      SHUNT Liver Diagnostic Kit (Test) for likelihood of large esophageal varices. Our HALT-C&#xD;
      Training dataset demonstrated that the DSI 18.3 had sensitivity 95%, specificity 54%, PPV&#xD;
      19%, NPV &gt;99%, negative likelihood ratio (NLR) 0.09, and positive likelihood ratio (PLR) 2.09&#xD;
      for large varices. To validate DSI 18.3 as a cutoff for large varices, we will enroll 420&#xD;
      subjects with chronic liver disease (CLD) of mixed etiologies from 15 to 25 US clinical&#xD;
      centers (CLD Validation dataset). The target prevalence of large varices is ≥20%. Each&#xD;
      subject will have been scheduled for an esophago-gastro-duodenoscopy (EGD) as part of their&#xD;
      standard of care for either variceal or non-variceal indications. Enrolled subjects will&#xD;
      undergo standard clinical assessment, laboratory tests, and the HepQuant SHUNT Test. The EGD&#xD;
      will be performed within 6 weeks following the HepQuant SHUNT Test. The relationship of DSI&#xD;
      to large varices will be analyzed by univariate and multivariate logistic regression&#xD;
      analyses, AUROC, and linear and nonlinear regression and correlation coefficients. Diagnostic&#xD;
      performance of the DSI cutoff will be defined in the CLD Validation dataset and validated for&#xD;
      likelihood of large esophageal varices. The validated DSI cutoff will identify subjects who&#xD;
      are either unlikely or likely to have large esophageal varices.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 23, 2019</start_date>
  <completion_date type="Actual">May 7, 2021</completion_date>
  <primary_completion_date type="Actual">May 7, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All subjects receive HepQuant SHUNT test and DSI measurement prior to a SOC EGD, to be done within 42 days of the SHUNT test. HepQuant SHUNT is a combination product where 13C Cholate 20mg is administered intravenously once for each test and d4 Cholate 40mg is administered once orally for each test</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DSI less than/equal to 18.3</measure>
    <time_frame>1 day</time_frame>
    <description>The primary objective of this study is to measure the subjects' liver function using DSI ≤18.3 for those that are not likely to have large esophageal varices.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>DSI greater than 18.3</measure>
    <time_frame>1 day</time_frame>
    <description>Secondary objective is to measure the subjects' liver function using DSI &gt;18.3 for those subjects who are likely to have large esophageal varices.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">311</enrollment>
  <condition>Chronic Liver Disease</condition>
  <arm_group>
    <arm_group_label>Open Label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects receive HepQuant SHUNT Liver Diagnostic Test within 42 days of the scheduled EGD. Test includes 20mg of 13C Cholate mixed with Albumin via IV push, and 40mg of d4 Cholate mixed with juice orally, both doses given simultaneously one time.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>HepQuant SHUNT Liver Diagnostic Test</intervention_name>
    <description>One time testing using the HepQuant SHUNT Liver Diagnostic Test kit (the combination product) in subjects with CLD and undergoing a standard of care EGD. The SHUNT test will be completed prior to the EGD. Each subject will receive an IV push dose of 13C Cholate mixed with Albumin simultaneously with an oral dose of d4 Cholate</description>
    <arm_group_label>Open Label</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability to have a peripheral venous catheter for administration of the 13C cholate&#xD;
&#xD;
          -  Ability to take the oral dose of d4-cholate&#xD;
&#xD;
          -  Ability to hold morning doses of medications for the 90-minute duration of the&#xD;
             HepQuant SHUNT Test&#xD;
&#xD;
          -  Meets the protocol defined criteria for CLD in addition to having the diagnoses of CLD&#xD;
             for &gt;6 months&#xD;
&#xD;
          -  Is scheduled, or in the process of being scheduled, for a standard of care EGD&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable to give informed consent&#xD;
&#xD;
          -  Unable to obtain venous access for administration of intravenous cholate&#xD;
&#xD;
          -  Unable to absorb orally-administered cholate&#xD;
&#xD;
          -  Known hypersensitivity to human serum albumin&#xD;
&#xD;
          -  Known hypersensitivity to any of the components of the HepQuant SHUNT Liver Diagnostic&#xD;
             Kit&#xD;
&#xD;
          -  Acute hepatitis or Acute Liver Failure&#xD;
&#xD;
          -  Acute drug-induced liver disease (DILI)&#xD;
&#xD;
          -  Noncirrhotic causes for portal hypertension and varices&#xD;
&#xD;
          -  Ongoing active alcoholic hepatitis&#xD;
&#xD;
          -  Child-Pugh class C defined by Child-Pugh score 10 or higher&#xD;
&#xD;
          -  Dialysis&#xD;
&#xD;
          -  Active infection or febrile illness within the last month&#xD;
&#xD;
          -  Documented history of esophageal or gastric variceal hemorrhage&#xD;
&#xD;
          -  Documented history of treatment of esophageal varices&#xD;
&#xD;
          -  Documented history of endoscopic findings of large esophageal varices&#xD;
&#xD;
          -  Hepatocellular carcinoma beyond Milan or UCSF criteria&#xD;
&#xD;
          -  Thrombosis of main portal vein&#xD;
&#xD;
          -  Liver transplant recipient&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Women who are breast-feeding&#xD;
&#xD;
          -  Serious intercurrent medical or surgical illness, such as acute myocardial infarction,&#xD;
             acute cerebral hemorrhage, sepsis, or other immediate life-threatening illness&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Greg Everson, MD</last_name>
    <role>Study Director</role>
    <affiliation>HepQuant, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Liver Health</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern CA Research Center</name>
      <address>
        <city>Coronado</city>
        <state>California</state>
        <zip>92118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Liver Research Institute</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inland Empire Liver Foundation</name>
      <address>
        <city>Rialto</city>
        <state>California</state>
        <zip>92377</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peak Gastroenterlogy Associates</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nature Coast Clinical Research</name>
      <address>
        <city>Inverness</city>
        <state>Florida</state>
        <zip>34452</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic, Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accel Research Sites</name>
      <address>
        <city>Orange City</city>
        <state>Florida</state>
        <zip>32763</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Associates of Pensacola</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Health Partners, PLLC</name>
      <address>
        <city>New Albany</city>
        <state>Indiana</state>
        <zip>47150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tandem Clinical Research</name>
      <address>
        <city>Marrero</city>
        <state>Louisiana</state>
        <zip>70072</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Digestive Disease Associates</name>
      <address>
        <city>Catonsville</city>
        <state>Maryland</state>
        <zip>21228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic, Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Louis University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lucas Research (Diabetes &amp; Endocrinology Consultants, PC)</name>
      <address>
        <city>Morehead City</city>
        <state>North Carolina</state>
        <zip>28557</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Pennsylvania Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ralph H Johnson Veterans Affairs Medical Center</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Dallas Liver Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor, Scott &amp; White</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intermountain Healthcare</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bon Secours, Newport News</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bon Secours, Richmond</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Consultants of SW VA</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of WA</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 20, 2018</study_first_submitted>
  <study_first_submitted_qc>July 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2018</study_first_posted>
  <last_update_submitted>August 27, 2021</last_update_submitted>
  <last_update_submitted_qc>August 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

